# Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)

> **NCT02358044** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 257 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** Sofosbuvir
- **BIOLOGICAL:** PegIntron
- **DRUG:** Ribavirin
- **DRUG:** Grazoprevir/Elbasvir (100 mg/50 mg) FDC

## Key facts

- **NCT ID:** NCT02358044
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-27
- **Primary completion:** 2015-11-26
- **Final completion:** 2016-02-16
- **Target enrollment:** 257 (ACTUAL)
- **Last updated:** 2018-10-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02358044

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02358044, "Efficacy and Safety of Combination Grazoprevir (MK-5172)/Elbasvir (MK-8742) Versus Sofosbuvir + Pegylated Interferon + Ribavirin in Hepatitis C Virus Genotype 1, 4 or 6 Infection (MK-5172-077)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT02358044. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*